RecruitMe Clinical Trial

ADVL1416, A Phase 1 study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid tumors, including CNS Tumors
A study for children with refractory solid tumors, including CNS tumors using study drug ramucirumab
Sponsor:Eli Lilly and Company
Enrolling:Male and Female Patients
Age Range:Between 1 and 21 years old
IRB Number:AAAQ5801
U.S. Government ID:NCT02564198
Contact: Alice Lee, MD: 212-305-5808 / al2041@cumc.columbia.edu
Additional Study Information:

The goals of this study are to find the highest safe dose of ramucirumab that can be given without causing severe side effects, to learn what kind of side effects ramucirumab can cause, to learn more about the effects of ramucirumab on cells and proteins in the blood and to determine whether ramucirumab is a beneficial treatment for patients with solid tumors.

Do You Qualify?
Has your child been diagnosed with solid tumors?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Alice Lee, MD
Email: al2041@cumc.columbia.edu
Phone: 212-305-5808